The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $65.41 as of October 15th.

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Walmart will become the first U.S. retailer to sell Abbott’s continuous glucose monitoring device as the medtech giant looks to broaden its sales potential for its growing business unit. | Walmart ...

Stifel has resumed coverage of several medtech companies, citing steady adoption of continuous glucose monitors (CGMs) and insulin pumps as key drivers for growth.

Hunterbrook asserted that some doctors stopped prescribing the G7 due to "disproportionate sensor inaccuracies, repeated ...

Walmart will become the first U.S. retailer to sell Abbott Laboratories' over-the-counter continuous glucose monitor Lingo in ...

Investing in bespoke processes can sidestep the inefficiencies of ‘lazy artificial intelligence (AI)’ in medical device ...

Experts weigh in on the most promising AI applications, from diabetic retinopathy screening to smarter insulin delivery, and ...

Rising Diabetes, Tech Innovations, and Home Care Models Drive CGM Adoption. Saudi Arabian Self-monitoring Blood Glucose ...

Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global ...

Saudi Arabia CGM Market Surges with Sensor Innovation, Home Care Trends, and Strategic Collaborations Driving Growth Amid Rising Diabetes PrevalenceDublin, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The "Saudi ...